Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X about a paper he co-authored with colleagues published in ESMO Open:
“In a recent report, ESMO Open, we show that a high FGFR2-IIIc to IIIb isoform ratio in gastric/GEJ cancer is associated with poor prognosis, EMT, and progression. Further analysis of the bemarituzumab-treated tumor is needed.”
Title: FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer
Authors: Sung Hee Lim, Takeshi Kuwata, Minae An, Jung Yong Hong, Seung Tae Kim, Yuki Matsubara, Kohei Shitara, Jeeyun Lee
Read the Full Article on ESMO Open.
More posts featuring Kohei Shitara.
